Diltiazem Market is anticipated to record a valuation of USD 369.95 million by 2028, a recent study by The Insight Partners

The Diltiazem market is projected to reach US$ 369.95 million by 2028 from US$ 832.51 million in 2021; it is expected to grow at a CAGR of 12.3% from 2021 to 2028.
Factors such as increase in cardiovascular disease incidence and increasing elderly population are driving the market growth. However, side effects of diltiazem is likely to hamper the growth of the market.
Heart diseases are mostly observed in elderly people due to their weak immunity and major other health problems. The general aging factors lead to stiffening the heart and blood vessels that lead to heart disorders. As the age grows, the systolic blood pressure also rises, and it can cause cardiovascular disease. Thus, high blood pressure is a common cause of heart conditions in people aged 75 years and above. Coronary artery disease and heart failure are the next caused conditions. Although the incidence of arrhythmias is encompassing people of all age groups, its incidence is rising significantly among elderly people.

Get Sample PDF Copy of Diltiazem Market at:
https://www.theinsightpartners.com/sample/TIPRE00021888/?utm_source=OpenPR&utm_medium=10408

According to the Global Ageing 2019 survey, the world's population of people aged 65 and above totaled 703 million in 2019. The elderly demographic is expected to double to 1.5 billion people by 2050. The frequency of one person aged 65 and above is likely to increase from 1 in every 11 inhabitants in 2019 to 1 in every six inhabitants by 2025. This demographic is more susceptible to CVDs, such as arrhythmias. Similarly, according to the WHO, the percentage of people aged 60 years and above is estimated to reach 22% by 2050 from 12% in 2015. According to the report "Older Americans 2016: Key Indicators of Well-Being" by the Federal Interagency Forum on Aging-Related Statistics, 35.8% of individuals with age 85 and above had a mild or extreme cognitive disorder. Moreover, according to the United Nation's World Population Ageing 2017 report, in 2017, there were 962 million people across the world who were aged 60 years and above, and the number is expected to reach nearly 2.1 billion by 2050.

Market Insights
Increase in Cardiovascular Disease Incidence
Diltiazem is a calcium channel blocker. It lowers the heart rate and works by relaxing blood vessels in the body and heart. Blood flows more easily, and the heart works less hard to pump blood. Diltiazem lowers myocardial oxygen demand through a reduction in heart rate, blood pressure, and cardiac contractility, also representing a good alternative for the treatment of stable chronic angina. Diltiazem has powerful cardiovascular effects caused by its actions on vascular smooth muscle, ventricular myocardium, and specialized conducting tissue. In individuals with normal ventricular function, it induces coronary and peripheral vasodilation, has a negative chronotropic and dromotropic impact, and has little to no negative inotropic effect. Diltiazem has potential use in a wide variety of cardiovascular disorders. It is extremely effective in relieving the coronary artery spasm associated with variant angina. When compared with nitrates in patients with exertional angina, diltiazem has similar efficacy.
According to the World Health Organization, cardiovascular diseases (CVDs) are the number one cause of death across the world. CVDs are a major cause of morbidity and affect more people than any other disease. A few CVDs are cerebrovascular disease, coronary heart disease, and rheumatic heart disease. Tobacco consumption, unhealthy diet, and physical inactivity are among major lifestyle factors that increase the risk of heart attacks and strokes. In addition, other risk factors that can lead to cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels.
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns.

Download the Latest COVID-19 Analysis on Diltiazem Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00021888/?utm_source=OpenPR&utm_medium=10408

Diltiazem Market: Competitive Landscape and Key Developments
Bausch Health; Teva Pharmaceutical Industries Ltd; Mylan N.V; Athenex; Pfizer, Inc; Glenmark; Sandoz (Novartis Ag); Sun Pharmaceutical Company Ltd; Hikma Pharmaceuticals; and Zydus Pharmaceuticals among the leading companies operating in the diltiazem market.
Based on product type, the diltiazem market is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market, whereas the capsules segment is expected to witness the fastest CAGR during the forecast period. Factors such as increase in cardiovascular disease incidence and increasing elderly population are driving the market growth. However, side effects of diltiazem is likely to hamper the growth of the market.

Order a Copy of Diltiazem Market Shares, Strategies and Forecasts 2021-2028 Research Report at:
https://www.theinsightpartners.com/buy/TIPRE00021888/?utm_source=OpenPR&utm_medium=10408

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defence, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

This release was published on openPR.